



David A. Tuveson, M.D., Ph.D.
SU2C Scientific Advisory Committee



David A. Tuveson, M.D., Ph.D.

Cold Spring Harbor Laboratory
Member, Stand Up To Cancer Scientific Advisory Committee
Cold Spring Harbor, NY

David Tuveson, M.D., Ph.D. completed chemistry at M.I.T., an M.D.-Ph.D. at Johns Hopkins, medical residency at Brigham and Women’s Hospital and a medical oncology fellowship at Dana-Farber/Harvard. While training, Tuveson co-developed KIT inhibitors with George Demetri for gastrointestinal stromal tumors, and Kras-dependent mouse cancer models with Tyler Jacks. At the University of Pennsylvania his lab generated the first mouse models of ductal pancreatic cancer, and at the University of Cambridge they identified new therapies. At Cold Spring Harbor Laboratory they developed organoid models of pancreatic cancer with Hans Clevers, enabling basic discoveries and clinical findings including signatures of “common responders” to chemotherapy. Tuveson is professor and director of Cold Spring Harbor Cancer Center, the chief scientist of the Lustgarten Foundation for Pancreatic Cancer Research, Cancer Center Director and Roy J. Zuckerberg Professor at CSHL, and serves on the Board of Scientific Advisors of the NCI, the Scientific Advisory Committee of Stand Up To Cancer and the Board of Directors of AACR. Awards include the Rita Allen, Waldenstrom and Hamdan.